Celestia S Higano
Affiliation: University of Washington
- Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancerEric J Small
UCSF Comprehensive Cancer Center, University of California, San Francisco, 1600 Divisadero St, Box 1711, San Francisco, CA 94115, USA
J Clin Oncol 24:3089-94. 2006..A phase III study was undertaken to evaluate the safety and efficacy of sipuleucel-T in a placebo-controlled study...
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancerCelestia S Higano
Department of Oncology and Urology, University of Washington, Seattle, WA, USA
Cancer 115:3670-9. 2009..The safety and efficacy of sipuleucel-T was evaluated in 2 identically designed, randomized, double-blind, placebo-controlled trials (D9901 and D9902A) conducted in men with advanced prostate cancer...
- Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumorsC S Higano
Departments of Medicine and Urology, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, USA
Invest New Drugs 33:450-62. 2015..The current study determined the recommended dose, safety, and pharmacokinetic (PK) profile of weekly or every-2-week dosing of cixutumumab...
- New and emerging agents for the treatment of castration-resistant prostate cancerCelestia S Higano
Department of Medicine, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Urol Oncol 29:S1-8. 2011..These realities make clinical trial design more challenging than ever...
- Sexuality and intimacy after definitive treatment and subsequent androgen deprivation therapy for prostate cancerCelestia S Higano
FACP, Seattle Cancer Care Alliance, Seattle, WA 98109 1023, USA
J Clin Oncol 30:3720-5. 2012..Suggestions for clinicians to better help patients and their partners regarding sexuality and intimacy are offered...
- New treatment options for patients with metastatic castration-resistant prostate cancerCelestia S Higano
University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Cancer Treat Rev 38:340-5. 2012....
- Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancerEvan Y Yu
University of Washington Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Clin Oncol 30:1864-70. 2012..To investigate changes in bone mineral density (BMD) and fracture risk in men who received intermittent androgen deprivation (IAD) for nonmetastatic, hormone-sensitive prostate cancer...
- Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinicianCelestia S Higano
Department of Medicine and Department of Urology, University of Washington, 825 Eastlake Avenue East, Mail Stop G3 200, Seattle, WA 98109, USA
Urol Clin North Am 31:331-52. 2004..Continuing trials may give us guidance in the future...
- Bone loss and the evolving role of bisphosphonate therapy in prostate cancerCelestia S Higano
Departments of Medicine and Urology, University of Washington School of Medicine, Seattle, WA 98109, USA
Urol Oncol 21:392-8. 2003..Whether zoledronic acid or other bisphosphonates might actually prevent or delay the development of bone metastases remains to be studied in randomized clinical trials...
- Management of bone loss in men with prostate cancerCelestia S Higano
Seattle Cancer Care Alliance, University of Washington, 98109, USA
J Urol 170:S59-63; discussion S64. 2003..Skeletal metabolism and osteoporosis in men, assessment of bone mineral density (BMD), effects of ADT on BMD, management strategies and potential therapies for osteopenia or osteoporosis in men with prostate cancer are reviewed...
- Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know?Celestia S Higano
University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Nat Clin Pract Urol 5:24-34. 2008..Future studies should address the long-term impact of antiresorptive therapy on actual fracture rate and the impact on quality of life and healthcare costs...
- Safety analysis of repeated high doses of samarium-153 lexidronam in men with hormone-naive prostate cancer metastatic to boneCelestia S Higano
Medicine and Urology, University of Washington Medical Center, Division of Medical Oncology, Seattle, WA 98109, USA
Clin Genitourin Cancer 6:40-5. 2008..The safety and tolerability of repetitive doses of the boneseeking radiopharmaceutical samarium-153 lexidronam (153Sm- EDTMP) were investigated in men with hormone-naive prostate cancer metastatic to bone...
- Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancerCelestia S Higano
University of Washington Medical Center, Seattle, Washington 98109, USA
Clin Cancer Res 10:1219-25. 2004....
- Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivationEvan Y Yu
Department of Medicine, Division of Oncology, University of Washington, 825 Eastlake Ave E, Seattle, WA 98109, USA
J Clin Oncol 28:2668-73. 2010....
- Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy SeriesColm Morrissey
Department of Urology, University of Washington, Seattle, WA 98195, USA
J Bone Miner Res 28:333-40. 2013..Furthermore, in this cohort of patients, BP treatment increased BV and did not decrease the number of osteoclasts in prostate cancer bone metastases compared with bone metastases from patients who did not receive BP...
- Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growthR Bruce Montgomery
Department of Medicine, University of Washington School of Medicine, Weattle, WA, USA
Cancer Res 68:4447-54. 2008..Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment...
- Histopathological assessment of prostate cancer bone osteoblastic metastasesMartine P Roudier
Department of Pathology, University of Washington and Research Service, Seattle, Washington, USA
J Urol 180:1154-60. 2008..The discrepancy between the radiological and clinical aspects of those events is not well understood. We better characterized the histopathology of bone processes in prostate cancer bone metastases...
- Metastases of prostate cancer express estrogen receptor-betaJanice S Lai
Department of Urology, University of Washington School of Medicine, Seattle, Washington 98195, USA
Urology 64:814-20. 2004..It has been proposed that ERbeta may play a role in the growth regulation of prostate cells. The targeting of ERs by selective ER modulators might be an effective method of treating advanced CaP...
- Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT InvestigatorsTomasz M Beer
Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR 97239, USA
J Clin Oncol 25:669-74. 2007..To compare the safety and activity of DN-101, a new high-dose oral formulation of calcitriol designed for cancer therapy, and docetaxel with placebo and docetaxel...
- Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxelTomasz M Beer
Department of Medicine, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Invest New Drugs 25:565-70. 2007..6%). One subject (2.6%) had a grade 4 treatment peripheral motor neuropathy. Further study of this dose and schedule of KOS-862 in this patient population cannot be recommended due to both lack of activity and excessive toxicity...
- Expression of the human cachexia-associated protein (HCAP) in prostate cancer and in a prostate cancer animal model of cachexiaZejing Wang
Department of Urology, University of Washington, Seattle, WA 98195, USA
Int J Cancer 105:123-9. 2003..Our results demonstrated that human CaP cells express HCAP and the expression of HCAP is associated with the progression of CaP and the development of CaP cachexia...
- Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastasesColm Morrissey
Genitourinary Cancer Research Laboratory, Department of Urology, University of Washington, Seattle, WA 98195, USA
Clin Exp Metastasis 25:377-88. 2008..In addition, the resulting tumor-associated microvessel density and distribution was significantly different between liver and bone metastasis possibly in response to the protein expression changes detailed above...
- Current status of treatment for patients with metastatic prostate cancerCelestia S Higano
Seattle Cancer Care Alliance, University of Washington, Seattle, WA 98109, USA
Can J Urol 12:38-41. 2005..Additional adjunctive therapy with the bisphosphonate, zoledronic acid, to reduce skeletal complications should be considered...
- Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastasesCanan Akfirat
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
J Pathol 230:291-7. 2013..Altogether, this suggests that optimal therapeutic inhibition may require combinations of drugs that target both bone and soft tissue-specific survival pathways...
- Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastasesSandy R Larson
Department of Urology, University of Washington, Seattle, Washington 98195, USA
Prostate 73:932-40. 2013..We determined whether previously identified and/or novel proteins were associated with the osteoblastic or osteolytic response in clinical specimens of PCa bone metastases...
- Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346)Catherine M Tangen
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
J Urol 188:1164-9. 2012..We also assessed whether any patient subsets benefited differentially during this period...
- Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to boneMartine P Roudier
Department of Urology, University of Washington, and Puget Sound VA Medical Center, Seattle, 98195, USA
Hum Pathol 34:646-53. 2003..Consequently, therapy directed to the phenotype of 1 metastasis may have no effect on other metastases in the same patient because of phenotypic heterogeneity...
- Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trialAmir Goldkorn
Department of Medicine, Division of Medical Oncology, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles, CA
Int J Cancer 136:1856-62. 2015..CTC telomerase activity thus merits further study and validation as a step towards molecular CTC-based precision cancer management...
- Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancerAmir Goldkorn
Amir Goldkorn, David I Quinn, and Tong Xu, University of Southern California Keck School of Medicine and Norris Comprehensive Cancer Center, Los Angeles Przemyslaw Twardowski, City of Hope, Duarte Philip C Mack and Primo Lara Jr, University of California, Davis, Sacramento, CA Benjamin Ely and Catherine M Tangen, Southwest Oncology Group Statistical Center Celestia S Higano, Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, and University of Washington, Seattle, WA Louis M Fink, Nevada Cancer Institute Nicholas J Vogelzang, Comprehensive Cancer Centers of Nevada and US Oncology Research, Las Vegas, NV Peter J Van Veldhuizen, University of Kansas Cancer Center, Westwood, KS Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT Michael A Carducci, Johns Hopkins Kimmel Cancer Center and Eastern Cooperative Oncology Group, Baltimore, MD J Paul Monk III, Ohio State University and Cancer and Leukemia Group B, Columbus, OH Ram H Datar and Richard J Cote, University of Miami Miller School of Medicine, Miami, FL Mark Garzotto, Portland Veterans Affairs Medical Center, Portland, Kitakobayashi 880
J Clin Oncol 32:1136-42. 2014..We assessed the prognostic value of CTCs for overall survival (OS) and disease response in S0421, a phase III trial of docetaxel plus prednisone with or without atrasentan...
- Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15Chung Ying Huang
Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98105 1024, USA
Clin Cancer Res 13:5825-33. 2007..To identify molecular alterations associating with in vivo exposure of prostate carcinoma to chemotherapy and assess functional roles modulating tumor response and resistance...
- Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancerEvan Y Yu
University of Washington School of Medicine, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
J Urol 188:103-9. 2012..We investigated this screening failure rate to promote better classification of patients thought to have nonmetastatic castration resistant prostate cancer and inform the design of future clinical trials in this setting...
- Positive surgical margins: the argument for androgen deprivation and chemotherapyCelestia S Higano
Department of Urology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Urol Oncol 27:89-91. 2009....
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher
Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Lancet 375:1437-46. 2010..Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, we assessed the antitumour activity and safety of MDV3100 in men with this disease...
- Darbepoetin alfa administered every 4 weeks for anemia in patients with advanced prostate cancerTomasz M Beer
Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA
Clin Genitourin Cancer 5:329-33. 2007..We sought to determine if infrequent dosing of darbepoetin alfa is safe and effective in treating anemia in patients receiving systemic therapy for prostate cancer...
- Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancerIlona N Holcomb
Divisions of Human Biology, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington, USA
Cancer Res 69:7793-802. 2009..Our investigation lays the foundation for a better understanding of and possible therapeutic targets for CR disease, the poorly responsive and final stage of prostate cancer...
- Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCelestia S Higano
Department of Oncology, University of Washington Seattle, Seattle, Washington, USA
Cancer 113:975-84. 2008..The immunotherapy, based on the GVAX platform, consisted of 2 allogeneic prostate-carcinoma cell lines modified to secrete granulocyte-macrophage-colony-stimulating factor (GM-CSF)...
- To treat or not to treat, that is the question: the role of bone-targeted therapy in metastatic prostate cancerCelestia S Higano
University of Washington, Seattle, WA
J Clin Oncol 32:1107-11. 2014..A prostate biopsy revealed Gleason 4+4 adenocarcinoma of the prostate. Androgen deprivation therapy with leuprolide acetate was initiated, and the addition of a bone-targeted agent was considered. ..
- A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumorsXiaoyu Qu
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 8:e74671. 2013..64, P<0.001). Overall, the three-marker FISH panel may represent a useful tool for risk stratification of prostate cancer patients. ..
- Enzalutamide, a second generation androgen receptor antagonist: development and clinical applications in prostate cancerManoj P Menon
University of Washington and Fred Hutchinson Cancer Research Center, c o Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Curr Oncol Rep 15:69-75. 2013..Some of the new challenges confronting the field regarding sequencing and combinations of these agents and the potential for a change in the natural history of the disease, are also discussed...
- Side effects of androgen deprivation therapy: monitoring and minimizing toxicityCelestia S Higano
Department of Urology, University of Washington School of Medicine, University of Washington, Seattle Cancer Care Alliance, Seattle, Washington 98109, USA
Urology 61:32-8. 2003..These side effects need more systematic study in clinical trials. Physicians should be aware of far-reaching consequences of ADT and should incorporate strategies for preventing and managing toxicities into routine practice...
- Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancerEva Corey
Department of Urology, University of Washington, Seattle, Washington 98195, USA
Clin Cancer Res 9:295-306. 2003..In this study we have examined the effects of zoledronic acid (ZA), a new-generation bisphosphonate, on prostate cancer (CaP) cells in vitro, and on both osteoblastic and osteolytic CaP metastases in animal models...
- Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomesRyan R Gordon
Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
PLoS ONE 9:e104271. 2014..As MAOA inhibitors have been approved for human use, regimens combining MAOA inhibitors with docetaxel may improve clinical outcomes. ..
- Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axisElahe A Mostaghel
Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Department of Medicine, University of Washington School of Medicine, Seattle, Washington, United States of America
PLoS ONE 9:e111545. 2014..We hypothesized that the efficacy of inhibiting DHT ligand synthesis would associate with intra-tumoral androgen ratios indicative of relative dependence on DHT-mediated growth...
- The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancerOliver Sartor
Department of Medicine, Tulane University, New Orleans, Louisiana 70115, USA
Urology 75:623-9. 2010..This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment...
- Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot studyMonique M Cherrier
Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA 98195, USA
BMC Cancer 10:1. 2010..A common treatment option for men with prostate cancer is androgen deprivation therapy (ADT). However, men undergoing ADT may experience physical side effects, changes in quality of life and sometimes psychiatric and cognitive side effects...
- Intermittent androgen deprivation: clinical experience and practical applicationsJonathan L Wright
Department of Urology, University of Washington, Seattle, WA 98195, USA
Urol Clin North Am 33:167-79, vi. 2006..This article discusses the theoretical benefits and rationale of IAD and reviews the completed and on-going IAD trials. Finally, the controversies, practical applications, and future directions of IAD are addressed...
- Does chemotherapy have a role before hormone-resistant disease develops?James P Dean
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Seattle, WA 98109, USA
Curr Urol Rep 10:226-35. 2009..This review discusses the status of chemotherapy in prostate cancer and addresses evidence regarding the use of chemotherapy in hormone-sensitive disease, alone and in combination with androgen deprivation therapy...
- C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapyEvan Y Yu
Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
Clin Nucl Med 36:192-8. 2011....
- Castration-Resistant Prostate Cancer Bone Metastasis Response Measured by 18F-Fluoride PET After Treatment with Dasatinib and Correlation with Progression-Free Survival: Results from American College of Radiology Imaging Network 6687Evan Y Yu
University of Washington, Seattle, Washington
J Nucl Med 56:354-60. 2015..18)F-fluoride PET quantitatively images bone metabolism and may serve as a pharmacodynamic assessment for systemic therapy such as dasatinib, a potent SRC kinase inhibitor, with activity in bone...
- Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733Celestia S Higano
Department of Medicine, Division of Oncology, University of Washington, Seattle, Washington, USA
Cancer 112:2181-7. 2008..Many patients with invasive urothelial cell cancer are poor candidates for cisplatin-based chemotherapy, and many are high risk for cystectomy. Southwest Oncology Group Trial 8733 was designed to address treatment for such patients...
- Elevation of cytokine levels in cachectic patients with prostate carcinomaJesco Pfitzenmaier
Department of Urology, University of Washington, Seattle, Washington 98195, USA
Cancer 97:1211-6. 2003..The objective of the current study was to determine whether cachexia associated with advanced CaP is accompanied by increased serum levels of TNFalpha, IL-1beta, IL-6, and IL-8...
- PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccineMartin A Cheever
Clinical Research Division, Fred Hutchinson Cancer Research Center, and Division of Medical Oncology, University of Washington, Seattle, WA 98109, USA
Clin Cancer Res 17:3520-6. 2011..The preclinical and clinical development of sipuleucel-T is reviewed, and approaches to enhance efficacy are considered herein...
- Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 ResultsMichael J Morris
Michael J Morris, Steven M Larson, and Howard I Scher, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY Arturo Molina, Thian Kheoh, Shannon L Matheny, Vahid Naini, and Thomas W Griffin, Janssen Research and Development, Los Angeles Eric J Small and Charles J Ryan, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA Johann S de Bono, Institute for Cancer Research and Royal Marsden Hospital, Sutton, United Kingdom Christopher J Logothetis, MD Anderson Cancer Center, Houston, TX Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France Paul de Souza, University of Western Sydney School of Medicine, Ingham Institute, Liverpool, New South Wales, Australia Philip W Kantoff, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA Celestia S Higano, University of Washington, Seattle, WA Jinhui Li, Janssen Research and Development, Harvard School of Public Health
J Clin Oncol 33:1356-63. 2015..A reproducible quantitative definition of radiographic PFS (rPFS) was tested for association with a coprimary end point of OS in a randomized trial of abiraterone in patients with mCRPC...
- Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion studyMatthew R Smith
Matthew R Smith, Massachusettes General Hospital Christopher J Sweeney, Aymen Elfiky, Dana Farber Cancer Institute, Boston, MA Paul G Corn, Christopher J Logothetis, MD Anderson Cancer Center, Houston, TX Dana E Rathkopf, Howard I Scher, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY David C Smith, Maha Hussain, University of Michigan, Ann Arbor, MI Daniel J George, Duke University Medical Center, Durham Ethan M Basch, University of North Carolina, Chapel Hill, NC Celestia S Higano, University of Washington, Seattle, WA Andrea L Harzstark, University of California San Francisco, San Francisco Christian Scheffold, A Douglas Laird, Frauke Schimmoller, Exelixis, South San Francisco, CA A Oliver Sartor, Tulane Cancer Center, Tulane University, New Orleans, LA Nicholas J Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, Maternal and Fetal Research Unit
J Clin Oncol 32:3391-9. 2014..Cabozantinib (XL184), an oral inhibitor of multiple receptor tyrosine kinases such as MET and VEGFR2, was evaluated in a phase II nonrandomized expansion study in castration-resistant prostate cancer (CRPC)...
- Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cellsJames D Lord
Department of Medicine, University of Washington, Seattle, WA, USA
Dig Dis Sci 55:1396-405. 2010..However, we found no evidence of FOXP3(+) T cell depletion in any of the nine patients who developed colitis...
- Genetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancerChristine M Barnett
Authors Affiliations Knight Cancer Institute Department of Public Health and Preventive Medicine Knight Diagnostic Laboratories, Oregon Health and Science University Portland VA Medical Center, Portland, Oregon and Puget Sound Oncology Consortium, Seattle Cancer Care Alliance, University of Washington, Seattle, Washington
Clin Cancer Res 20:1306-12. 2014..We examined the prevalence of potentially therapeutically actionable mutations in patients with high-risk clinically localized prostate cancer...
- Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115 1711, USA
J Urol 170:S3-5. 2003
- Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancerJames L Gulley
Center for Cancer Research, Laboratory of Tumor Immunology and Biology, National Cancer Institute, Bethesda, Maryland 20892, USA
J Urol 180:1432-7; discussion 1437. 2008..To our knowledge this represents the largest study using monthly testosterone and dihydroxytestosterone measurement to evaluate the kinetics of androgen recovery following limited androgen deprivation therapy...
- Guideline for the management of clinically localized prostate cancer: 2007 updateIan Thompson
American Urological Association Education and Research, Inc
J Urol 177:2106-31. 2007
- Annual zoledronic acid: is less more?Celestia S Higano
J Clin Oncol 25:1026. 2007
- Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reMichael S Cookson
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA
J Urol 177:540-5. 2007....
- The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panelFred Saad
Universite de Montreal, Quebec, Canada
Clin Genitourin Cancer 4:257-62. 2006..However, further study of the use of bisphosphonates across the clinical spectrum of prostate cancer is needed...
- Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancerMatthew R Smith
Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
J Clin Oncol 23:2918-25. 2005..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
- Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapiesTerrence H Diamond
Department of Medicine, University of New South Wales, St George Hospital Campus, Sydney, Australia
Cancer 100:892-9. 2004..In the current review, the authors addressed the current research, diagnostic methods, and treatment recommendations for bone loss and osteoporosis in men with prostate carcinoma who received ADT...
- Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancerMark Garzotto
Urology Section, Surgical Service, Portland VA Medical Center, Portland, OR 97239, USA
Urol Oncol 24:254-9. 2006..The goal of this phase I/II study is to evaluate the safety and efficacy of neoadjuvant docetaxel and mitoxantrone before prostatectomy...
- A prospective analysis of the time to normalization of serum androgens following 6 months of androgen deprivation therapy in patients on a randomized phase III clinical trial using limited hormonal therapyJames L Gulley
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
J Urol 173:1567-71. 2005..We present the largest published series of patients evaluating the timing of T and DHT increase after cessation of GnRH therapy...
- Erectile function outcome reporting after clinically localized prostate cancer treatmentArthur L Burnett
The Johns Hopkins Hospital, 600 North Wolfe St, Marburg 407, Baltimore, Maryland 21287 2411, USA
J Urol 178:597-601. 2007....
- American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancerEthan M Basch
Memorial Sloan Kettering Cancer Center, New York, NY, USA
J Clin Oncol 25:5313-8. 2007..The review panel notes that CCO has published separate guidelines on radiopharmaceuticals and bisphosphonates in men with castration-resistant (ie, hormone-refractory) metastatic prostate cancer...
- Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancerTomasz M Beer
Divisions of Hematology and Medical Oncology, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, Portland, Oregon 97239, USA
Clin Cancer Res 10:1306-11. 2004..The purpose is to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of mitoxantrone and docetaxel administered weekly before prostatectomy in men with localized prostate cancer at high risk for recurrence...